作者
Fang-e Shi,Zhe Yu,Chuang Sun,Peiliang Gao,Haiyan Zhang,Jihong Zhu
摘要
ABSTRACTObjectives The aim of this study is to monitor, identify, and compare the adverse events (AEs) related to tenecteplase and alteplase, with the objective of exploring the potential safety of tenecteplase for acute ischemic stroke (AIS) and guiding its use to enhance patient safety.Methods In order to evaluate the disproportionality of AEs associated with tenecteplase and alteplase in real-world data, four algorithms (ROR, PRR, BCPNN, EBGM) were utilized as measures to detect signals of AEs related to both drugs. Subsequently, Breslow-Day statistical analysis was applied to compare the RORs of the main system organ classes (SOCs) and key preferred terms (PTs) between tenecteplase and alteplase.Results A statistical analysis was performed utilizing data gleaned from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, encompassing 19,514,140 case reports from 2004Q1 to 2023Q1. There were 1,004 cases where tenecteplase was reported as the primary suspected (PS) and 2,363 tenecteplase-related adverse drug reactions (ADRs) at the PTs level were identified, the two data of alteplase were 10,945 and 25,266, respectively. The occurrence of drug-induced ADRs was analyzed across 27 organ systems, The analysis revealed several expected ADRs, such as Haemorrhage, Hypersensitivity which were consistent with the two drug-labels. It is of note that the signal strengths of ‘death,’ ‘ventricular fibrillation,’ ‘cardiogenic shock’ and ‘pneumonia aspiration’ at the PT level were markedly higher for tenecteplase than for alteplase, whereas the signal strength of ‘angioedema’ at the PT level was significantly higher for alteplase in comparison to tenecteplase. Additionally, unexpected significant ADRs associated with ocular adverse reactions and pneumonia aspiration at the PT level were identified, indicating potential AEs not currently mentioned in the drug instructions.Conclusion This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of AIS patients undergoing thrombolytic therapy.KEYWORDS: TenecteplasealteplaseRORPRRBCPNNEBGM Declaration of interestsThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have received an honorarium from Expert Opinion on Drug Safety for their review work but have no other relevant financial relationships to disclose.Author contributionF Shi and J Zhu conceived and designed the analysis. Z Yu collected the data. C Sun, P Gao and H Zhang contributed data or analysis tools. F Shi performed the analysis. Z Yu wrote the paper. J Zhu did the supervision and revision of the manuscript.AcknowledgmentsThe data for this study was obtained from the FDA Adverse Event Reporting System (FAERS), which was provided by the FDA. The findings, conclusions, and interpretations of this study do not necessarily reflect the views or opinions of the FDA.Supplementary materialSupplemental data for this article can be accessed online at https://doi.org/10.1080/14740338.2023.2245745.Additional informationFundingThis paper was funded by the Peking University People’s Hospital Scientific Research Development Funds (PTU2021-02).